(DCTH).......
RECEIVES APPROVAL FOR PH II AND III TRIALS FROM FDA: Delcath Systems, Inc. (DCTH)
announced that the FDA has notified the Company that patient enrollment may resume in the
Phase III and Phase II clinical trials of the Delcath System. Current and prospective clinical investigation
sites have been notified that study accrual can be resumed immediately. Resumption
of study accrual follows a voluntary enrollment deferral announced by the Company on October
23, 2007 in response to an FDA inquiry into certain gastrointestinal adverse events observed
in four patients enrolled in the studies of the Delcath System prior to protocol changes enacted
earlier this year. The Company has been notified in writing by the FDA that the studies can proceed
with an amended protocol.
If the enacted as well the studies were success according to the sector that all was proven..
_________________
Ultrasound Repair (http://www.axessultrasound.com)
Double Bottom(reversal) chart pattern,technical rebound...
This New York City med tech stock had a monster run, corrected,
and is ready to run again.
Technicals
Last Price Quote is:
2.27%above 13-day MA
7.72%above 50-day MA
RS Rating: 60